{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:13:59Z","timestamp":1792174439390,"version":"4.4.0"},"reference-count":95,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:p>Background: Cerebrospinal fluid (CSF) or blood biomarkers like phosphorylated tau proteins (p-tau) are used to detect Alzheimer\u2019s disease (AD) early. Increasing studies on cognitive function and blood or CSF p-tau levels are controversial. Objective: Our study examined the potential of p-tau as a biomarker of cognitive status in normal control (NC), mild cognitive impairment (MCI), and AD patients. Methods: We searched PubMed, Cochrane, Embase, and Web of Science for relevant material through 12 January 2023. 5,017 participants from 20 studies\u20141,033 AD, 2,077 MCI, and 1,907 NC\u2014were evaluated. Quantitative analysis provided continuous outcomes as SMDs with 95% CIs. Begg tested publication bias. Results: MCI patients had lower CSF p-tau181 levels than AD patients (SMD\u200a=\u22120.60, 95% CI (\u22120.85, \u22120.36)) but higher than healthy controls (SMD\u200a=\u200a0.67). AD\/MCI patients had greater plasma p-tau181 levels than healthy people (SMD\u200a=\u22120.73, 95% CI (\u22121.04, \u22120.43)). MCI patients had significantly lower p-tau231 levels than AD patients in plasma and CSF (SMD\u200a=\u22120.90, 95% CI (\u22120.82, \u22120.45)). MCI patients showed greater CSF and plasma p-tau231 than healthy controls (SMD\u200a=\u200a1.34, 95% CI (0.89, 1.79) and 0.43, (0.23, 0.64)). Plasma p-tau181\/231 levels also distinguished the three categories. MCI patients had higher levels than healthy people, while AD patients had higher levels than MCI patients. Conclusions: CSF p-tau181 and p-tau231 biomarkers distinguished AD, MCI, and healthy populations. Plasma-based p-tau181 and p-tau231 biomarkers for AD and MCI need further study.<\/jats:p>","DOI":"10.3233\/jad-230799","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T10:35:56Z","timestamp":1707474956000},"page":"13-32","source":"Crossref","is-referenced-by-count":26,"title":["The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"98","author":[{"given":"Zhirui","family":"Li","sequence":"first","affiliation":[{"name":"Department of Disease Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Sichuan Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Fan","sequence":"additional","affiliation":[{"name":"School of Health Policy and Management, Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiamen Fifth Hospital, Fujian Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230799_ref1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000109998","article-title":"Prevalence of dementia in the United States: The aging, demographics, and memory study","volume":"29","author":"Plassman","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.3233\/JAD-230799_ref2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1582-4934.2008.00314.x","article-title":"Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer\u2019s disease","volume":"12","author":"Farfara","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.3233\/JAD-230799_ref3","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.3233\/JAD-230799_ref4","first-page":"e1","article-title":"Recent publications from the Alzheimer\u2019s Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials","volume":"13","author":"Weiner","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-230799_ref6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-230799_ref7","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-230799_ref8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-230799_ref9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.arr.2012.06.002","article-title":"Crosstalks between neurofibrillary tangles and amyloid plaque formation","volume":"12","author":"Luan","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-230799_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-4580(02)00057-X","article-title":"Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: A meta-analysis","volume":"24","author":"Lyness","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230799_ref11","first-page":"38","article-title":"Selective alterations of neurons and circuits related to early memory loss in Alzheimer\u2019s disease","volume":"8","author":"Llorens-Mart\u00edn","year":"2014","journal-title":"Front Neuroanat"},{"key":"10.3233\/JAD-230799_ref12","doi-asserted-by":"crossref","first-page":"e2378","DOI":"10.1212\/WNL.0000000000010629","article-title":"Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE \u025b4 genotype","volume":"95","author":"Babapour Mofrad","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-230799_ref13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/cells11050919","article-title":"Waste clearance in the brain and neuroinflammation: A novel perspective on biomarker and drug target discovery in Alzheimer\u2019s disease","volume":"11","author":"Uchida","year":"2022","journal-title":"Cells"},{"key":"10.3233\/JAD-230799_ref14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jalz.2018.05.016","article-title":"Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial","volume":"14","author":"Sano","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.dadm.2019.05.001","article-title":"Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Fossati","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-230799_ref17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230799_ref18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molmed.2005.02.009","article-title":"Alzheimer\u2019s disease: Abeta, tau and synaptic dysfunction","volume":"11","author":"LaFerla","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.3233\/JAD-230799_ref19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.4103\/0366-6999.235112","article-title":"Research progress in the pathogenesis of Alzheimer\u2019s disease","volume":"131","author":"Chen","year":"2018","journal-title":"Chin Med J (Engl)"},{"key":"10.3233\/JAD-230799_ref20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-230799_ref21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230799_ref22","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med"},{"key":"10.3233\/JAD-230799_ref23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-230799_ref24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/jnnp-2021-327370","article-title":"Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: A focused review on recent advances","volume":"92","author":"Chong","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-230799_ref25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230799_ref26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230799_ref27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1749-6632.1996.tb34410.x","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer\u2019s disease","volume":"777","author":"Goedert","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-230799_ref28","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-230799_ref29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","article-title":"Plasma biomarkers for Alzheimer\u2019s Disease in relation to neuropathology and cognitive change","volume":"143","author":"Smirnov","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230799_ref30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.3233\/JAD-230799_ref31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ana.26308","article-title":"Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults","volume":"91","author":"Meyer","year":"2022","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230799_ref32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230799_ref33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2022.03.018","article-title":"P-tau217 in Alzheimer\u2019s disease","volume":"531","author":"Telser","year":"2022","journal-title":"Clin Chim Acta"},{"key":"10.3233\/JAD-230799_ref34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230799_ref35","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"key":"10.3233\/JAD-230799_ref36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-150167","article-title":"Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer\u2019s disease","volume":"49","author":"Spiegel","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230799_ref37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/jamaneurol.2013.2110","article-title":"Prognosis of mild cognitive impairment in early Parkinsondisease: The Norwegian ParkWest study","volume":"70","author":"Pedersen","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230799_ref38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease","volume":"1362","author":"Thorsell","year":"2010","journal-title":"Brain Res"},{"key":"10.3233\/JAD-230799_ref39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cns.12814","article-title":"Evaluation of cerebrospinal fluid phosphorylated tau(231) as a biomarker in the differential diagnosis of Alzheimer\u2019s disease and vascular dementia","volume":"24","author":"Ki\u0111emet-Piska\u010d","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.3233\/JAD-230799_ref40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JAD-230799_ref41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0361-9230(03)00087-X","article-title":"Advances in the development of biomarkers for Alzheimer\u2019s disease: From CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein","volume":"61","author":"Hampel","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.3233\/JAD-230799_ref42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pedhc.2021.04.011","article-title":"PRISMA 2020: An update","volume":"35","author":"Swartz","year":"2021","journal-title":"J Pediatr Health Care"},{"key":"10.3233\/JAD-230799_ref43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","article-title":"Validation of a short Orientation-Memory-Concentration Test of cognitive impairment","volume":"140","author":"Katzman","year":"1983","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-230799_ref44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.3233\/JAD-230799_ref45","first-page":"1","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"2","author":"Peterson","year":"2011","journal-title":"Ottawa Hospital Research Institute"},{"key":"10.3233\/JAD-230799_ref46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: A follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230799_ref47","doi-asserted-by":"crossref","first-page":"fcab136","DOI":"10.1093\/braincomms\/fcab136","article-title":"Association of plasma P-tau181 with memory decline in non-demented adults","volume":"3","author":"Therriault","year":"2021","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-230799_ref48","doi-asserted-by":"crossref","first-page":"101771","DOI":"10.1016\/j.nicl.2019.101771","article-title":"Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging","volume":"22","author":"Ottoy","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-230799_ref49","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/jcm8111893","article-title":"Associations between plasma biomarkers and cognition in patients with Alzheimer\u2019s disease and amnestic mild cognitive impairment: A cross-sectional and longitudinal study","volume":"8","author":"Tsai","year":"2019","journal-title":"J Clin Med"},{"key":"10.3233\/JAD-230799_ref50","doi-asserted-by":"crossref","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","article-title":"Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET","volume":"76","author":"Tissot","year":"2022","journal-title":"EBioMedicine"},{"key":"10.3233\/JAD-230799_ref51","doi-asserted-by":"crossref","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","article-title":"Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays","volume":"97","author":"Leuzy","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-230799_ref52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-141986","article-title":"Diagnostic accuracy of cerebrospinal fluid amyloid-\u03b2 isoforms for early and differential dementia diagnosis","volume":"45","author":"Struyfs","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230799_ref53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/neurolint14020029","article-title":"Diagnostic accuracy of the Five-Word Test for mild cognitive impairment due to Alzheimer\u2019s disease","volume":"14","author":"Fornari","year":"2022","journal-title":"Neurol Int"},{"key":"10.3233\/JAD-230799_ref54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref55","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3233\/JAD-215646","article-title":"Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer\u2019s disease","volume":"87","author":"Pilotto","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-230799_ref56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-020-00407-2","article-title":"Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration","volume":"15","author":"Franzmeier","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-230799_ref57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2005.08.030","article-title":"Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment","volume":"391","author":"Buerger","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-230799_ref58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(02)01038-8","article-title":"Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment","volume":"333","author":"de Leon","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-230799_ref59","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/01.wnl.0000271375.37131.04","article-title":"Longitudinal changes of CSF biomarkers in memory clinic patients","volume":"69","author":"Bouwman","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-230799_ref60","first-page":"141","article-title":"Quantitative structural MRI and CSF biomarkers in early diagnosis of Alzheimer\u2019s disease","author":"Brys","year":"2011","journal-title":"Handbook of Imaging the Alzheimer Brain"},{"key":"10.3233\/JAD-230799_ref61","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.neurobiolaging.2011.05.013","article-title":"Serial CSF sampling in Alzheimer\u2019s disease: Specific versus non-specific markers","volume":"33","author":"Kester","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-230799_ref62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000318738","article-title":"Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment","volume":"30","author":"Riepe","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-230799_ref63","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/jnnp.2008.167791","article-title":"CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer\u2019s disease: A meta-analysis of 51 studies","volume":"80","author":"Mitchell","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-230799_ref64","doi-asserted-by":"crossref","first-page":"e12921","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-230799_ref65","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.3233\/JAD-230799_ref66","doi-asserted-by":"crossref","first-page":"103936","DOI":"10.1016\/j.ebiom.2022.103936","article-title":"CSF p-tau231: A biomarker for early preclinical Alzheimer?","volume":"77","author":"Su\u00e1rez-Calvet","year":"2022","journal-title":"EBioMedicine"},{"key":"10.3233\/JAD-230799_ref67","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-230799_ref68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-230799_ref69","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref70","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"10.3233\/JAD-230799_ref71","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4103\/aian.aian_77_22","article-title":"P-tau231 as a diagnostic biomarker for Alzheimer\u2019s disease and mild cognitive impairment: A systematic review and meta-analysis","volume":"25","author":"Nabizadeh","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"10.3233\/JAD-230799_ref72","doi-asserted-by":"crossref","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease","volume":"76","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"key":"10.3233\/JAD-230799_ref73","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/archneur.62.5.770","article-title":"Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease","volume":"62","author":"Hampel","year":"2005","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230799_ref74","doi-asserted-by":"crossref","unstructured":"Ahmadian N , Talebi N , Mahmoudi J , Etegad SS , Aghili A (2019) Cerebrospinal fluid tau and phosphotau as biomarkers in Alzheimer\u2019s disease diagnosis. Basic Clin Neurosci, doi: http:\/\/dx.doi.org\/10.32598\/bcn.9.10.445","DOI":"10.32598\/bcn.9.10.445"},{"key":"10.3233\/JAD-230799_ref75","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00702-014-1226-y","article-title":"Does CSF p-tau181 help to discriminate Alzheimer\u2019s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature","volume":"121","author":"Tang","year":"2014","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JAD-230799_ref76","doi-asserted-by":"crossref","first-page":"A453","DOI":"10.1016\/j.jval.2014.08.1235","article-title":"Efficacy of the phosphorylated tau P181 for the Alzheimer\u2019s disease dementia \u2013 a systematic review and meta analysis","volume":"17","author":"Mo","year":"2014","journal-title":"Value Health"},{"key":"10.3233\/JAD-230799_ref77","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1002\/jcp.29362","article-title":"Outer membrane vesicles enhance tau phosphorylation and contribute to cognitive impairment","volume":"235","author":"Wei","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.3233\/JAD-230799_ref78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/pharmaceutics14020411","article-title":"Delivery of intravenously administered antibodies targeting Alzheimer\u2019s disease-relevant tau species into the brain based on receptor-mediated transcytosis","volume":"14","author":"Tashima","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.3233\/JAD-230799_ref79","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/biomedicines10040742","article-title":"Addressing blood-brain barrier impairment in Alzheimer\u2019s disease","volume":"10","author":"Sharma","year":"2022","journal-title":"Biomedicines"},{"key":"10.3233\/JAD-230799_ref80","doi-asserted-by":"crossref","first-page":"688090","DOI":"10.3389\/fnins.2021.688090","article-title":"Blood-brain barrier breakdown: An emerging biomarker of cognitive impairment in normal aging and dementia","volume":"15","author":"Hussain","year":"2021","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-230799_ref81","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s44161-021-00014-4","article-title":"Blood-brain barrier link to human cognitive impairment and Alzheimer\u2019s disease","volume":"1","author":"Barisano","year":"2022","journal-title":"Nat Cardiovasc Res"},{"issue":"Suppl 5","key":"10.3233\/JAD-230799_ref82","doi-asserted-by":"crossref","first-page":"e057860","DOI":"10.1002\/alz.057860","article-title":"Plasma p-Tau181 and p-Tau231 offer complementary information to identify Alzheimer\u2019s disease pathophysiology","volume":"17","author":"Ferreira","year":"2021","journal-title":"Alzheimers Dementia"},{"key":"10.3233\/JAD-230799_ref83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230799_ref84","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-230799_ref85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00702-022-02468-7","article-title":"Proteinopathies: Molecular mechanisms and diagnostic perspectives","volume":"129","author":"Delaby","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JAD-230799_ref87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref88","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14382"},{"key":"10.3233\/JAD-230799_ref89","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX (N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-230799_ref90","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref91","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230799_ref93","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2016.08.003","article-title":"Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg\/mL levels of cytokines in human serum","volume":"437","author":"Yeung","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.3233\/JAD-230799_ref94","first-page":"e12137","article-title":"Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF","volume":"12","author":"Hansson","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-230799_ref95","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:28Z","timestamp":1777370968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":95,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-230799","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}